NewsData says Cuban COVID Vaccines Highly Effective

St. Lucia News OnlineJuly 4, 202229159 min
Cuba has long punched above its weight when it comes to healthcare and biotechnology. Ernesto Mastrascusa/EPA-EFE

Republished Article:

By Michael Head

Senior Research Fellow in Global Health, University of Southampton


The western world has written plenty about its high-profile COVID vaccines: the mRNA products of Pfizer and Moderna, viral-vectored jabs from AstraZeneca and Johnson & Johnson, and those that are just emerging, such as Novavax’s protein-based vaccine. Many countries are relying on them for protection.

But not Cuba. It’s been quietly working on its own vaccines, immunizing its population and selling doses abroad.

Cuba’s vaccine efforts have maintained a relatively low profile in the west to date. Politics may well be a reason. The US embargo against Cuba that began in the cold war is still in effect, and tensions between the countries remain high.

But for those familiar with Cuba, its COVID vaccine development should come as no surprise – the country has a long history of manufacturing its own vaccines and medicines. Nor should it be surprising that two of its COVID vaccines – Abdala and Soberana 02 – appear to have performed very well in trials. 

Here’s how they work.

Abdala is a protein subunit vaccine, which is a well-established design. The hepatitis B vaccine and Novavax COVID vaccine use this approach. These vaccines work by delivering just a portion of the virus that they’re targeted against – in the case of Abdala, bits of the coronavirus’s spike proteins, which cover its exterior.

The proteins used in the vaccine aren’t taken from the coronavirus directly. Instead, they’re grown in cells of a yeast (Pichia pastoris) that’s been specially engineered.

Cuba has long punched above its weight when it comes to healthcare and biotechnology. Ernesto Mastrascusa/EPA-EFE

On their own, the portions of spike protein are harmless. But when the immune system encounters them, it still trains itself to recognise and destroy them. If the full coronavirus is then encountered in the future, the body will attack these outer parts of the virus and quickly destroy it. Abdala is given in three doses.

The other Cuban COVID vaccine, Soberana 02, uses a “conjugate” design, along the lines of meningitis or typhoid vaccines. It contains a different part of the spike protein to Abdala and generates an immune response by attaching (conjugating) this to a harmless extract from the tetanus toxin. When the body encounters these linked together, it launches a stronger immune response than it would to either alone.

Soberana 02 is produced in hamster ovary cells, a process that can be slow, and this may restrict large-scale manufacturing.

Originally, it was given as two doses, but researchers later identified that a third dose would be beneficial. This booster dose contains just the spike protein parts, without the tetanus toxin, and is known as “Soberana Plus”.

How effective are they?

Both vaccines have been approved by the Cuban regulator, though they started being rolled out in May – before authorization had been granted – in response to a rise in cases. There have been concerns about a lack of information on their safety and efficacy.

On November 1 2021, a preprint (research still awaiting review) was finally published of a Soberana phase 3 trial that included 44,031 participants. The results suggest that two doses of Soberana 02 with a booster of Soberana Plus are together 92% protective against symptomatic COVID. The preprint notes that during the trial, the vaccine was most likely being tested against Beta or Delta – two variants of the coronavirus that other vaccines have found harder to control.

Before this, a phase 1 study of giving Soberana Plus to people who had already had COVID was published in September. This was testing the effects of Soberana Plus as a booster to natural rather than vaccine-induced immunity. It showed no safety issues and stimulated a good immune response when used in this way – though the study was small, involving just 30 participants.

For Abdala, the only phase 3 trial data available was issued by Cuban press releases in June and July 2021. The three-dose schedule is also reportedly 92% protective against symptomatic COVID as well as allegedly fully protective against severe disease and death.

This generated huge enthusiasm within Cuba. However, since then little further information has been made publicly available. 

(This article appeared in the December 7, 2021 issue of The Conversation)

St. Lucia News Online

Leave a Reply

Your email address will not be published. Required fields are marked *

Saint Lucia News Online is an iconic design and visual news brand encompassing a venerated magazine, a website, one of the most well-respected online magazine petitions in the industry. Founded in 2017, Magazine seeks to build a dialogue about community by detailing the intersections of culture and society. Magazine focuses on a broad stroke of visual culture today, covering everything.


St. Lucia News Online, 2021 © All Rights Reserved.